Literature DB >> 1546523

Meningeal fibrosarcoma: a case report and review of the literature.

A Rovirosa1, P Vicente, J Bellmut, S Morales, J M Del Campo, R Bodi, A Ortega.   

Abstract

Meningeal Fibrosarcoma (MF) accounts only for 0.5% of the brain tumors. Since the clinical manifestations and radiologic findings are non-specific, the diagnosis can only be achieved by pathological examination of surgically removed specimens. MF are tumors that behave locally very aggressively and respond poorly to treatment, with reported median survivals ranging from 6 to 15 months. We report a new case of MF describing the peculiar onset as a slow growing mass in scalp with bone destruction and without neurological clinical findings.

Entities:  

Mesh:

Year:  1992        PMID: 1546523

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  5 in total

1.  The clinicoradiological features and surgical outcomes of primary intracranial fibrosarcoma: a single-institute experience with a systematic review.

Authors:  Xiu-Jian Ma; Da Li; Huan Li; Liang Wang; Shu-Yu Hao; Li-Wei Zhang; Jun-Ting Zhang; Zhen Wu
Journal:  Neurosurg Rev       Date:  2020-02-08       Impact factor: 3.042

Review 2.  Primary meningeal fibrosarcoma: a particular neuroradiological presentation.

Authors:  A Donnet; D Figarella-Branger; F Grisoli
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 3.  Primary intracranial fibrosarcoma with intratumoral hemorrhage: neuropathological diagnosis with review of the literature.

Authors:  P McDonald; A Guha; J Provias
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

Review 4.  A report of primary brain fibrosarcoma with literature review.

Authors:  Ning Cai; Leonard B Kahn
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

5.  Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib.

Authors:  Daniela Alexandru; Denise K Van Horn; Daniela Annenelie Bota
Journal:  J Neurooncol       Date:  2009-12-31       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.